Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
European Journal of Cancer · 2023-05 · 185 · 83-93
DOI: 10.1016/j.ejca.2023.02.023 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2023-05. Verfasst von Ryota Saito und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tohoku University, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Tohoku University, Sendai, Japan.
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
- Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan.
- Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.
Zitieren
APA
Saito, R., Sugawara, S., Ko, R., Azuma, K., Morita, R., Maemondo, M., Oizumi, S., Takahashi, K., Kagamu, H., Tsubata, Y., Seike, M., Kikuchi, T., Okamoto, I., Satoshi, M., Asahina, H., Tanaka, K., Sugio, K., & Kobayashi, K. (2023). Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer, 185, 83-93. https://doi.org/10.1016/j.ejca.2023.02.023
Vancouver
Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer. 2023;185:83-93. doi:10.1016/j.ejca.2023.02.023
BibTeX
@article{Saito2023,
author = {Saito, Ryota and Sugawara, Shunichi and Ko, Ryo and Azuma, Koichi and Morita, Ryo and Maemondo, Makoto and Oizumi, Satoshi and Takahashi, Kazuhisa and Kagamu, Hiroshi and Tsubata, Yukari and Seike, Masahiro and Kikuchi, Toshiaki and Okamoto, Isamu and Satoshi, Morita and Asahina, Hajime and Tanaka, Kentaro and Sugio, Kenji and Kobayashi, Kunihiko},
title = {Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study},
journal = {European Journal of Cancer},
year = {2023},
volume = {185},
pages = {83--93},
doi = {10.1016/j.ejca.2023.02.023}
}
EUVIMED